206 related articles for article (PubMed ID: 30912923)
1. Targeting the Oncogene KRAS Mutant Pancreatic Cancer by Synergistic Blocking of Lysosomal Acidification and Rapid Drug Release.
Kong C; Li Y; Liu Z; Ye J; Wang Z; Zhang L; Kong W; Liu H; Liu C; Pang H; Hu Z; Gao J; Qian F
ACS Nano; 2019 Apr; 13(4):4049-4063. PubMed ID: 30912923
[TBL] [Abstract][Full Text] [Related]
2. Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer.
Yuan F; Sun M; Liu Z; Liu H; Kong W; Wang R; Qian F
Theranostics; 2022; 12(3):1061-1073. PubMed ID: 35154474
[No Abstract] [Full Text] [Related]
3. pH-triggered charge-reversal and redox-sensitive drug-release polymer micelles codeliver doxorubicin and triptolide for prostate tumor therapy.
Xu C; Song RJ; Lu P; Chen JC; Zhou YQ; Shen G; Jiang MJ; Zhang W
Int J Nanomedicine; 2018; 13():7229-7249. PubMed ID: 30510415
[TBL] [Abstract][Full Text] [Related]
4. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment.
Wu B; Lu ST; Zhang LJ; Zhuo RX; Xu HB; Huang SW
Int J Nanomedicine; 2017; 12():1853-1862. PubMed ID: 28331310
[TBL] [Abstract][Full Text] [Related]
5. Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms.
Zhang YQ; Shen Y; Liao MM; Mao X; Mi GJ; You C; Guo QY; Li WJ; Wang XY; Lin N; Webster TJ
Nanomedicine; 2019 Jan; 15(1):86-97. PubMed ID: 30244085
[TBL] [Abstract][Full Text] [Related]
6. Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line.
Kim ST; Kim SY; Lee J; Kim K; Park SH; Park YS; Lim HY; Kang WK; Park JO
BMC Cancer; 2018 Nov; 18(1):1103. PubMed ID: 30419860
[TBL] [Abstract][Full Text] [Related]
7. Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine.
Wang C; Liu B; Xu X; Zhuang B; Li H; Yin J; Cong M; Xu W; Lu A
Oncotarget; 2016 Feb; 7(7):8360-72. PubMed ID: 26840019
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Cancer Angiogenesis Using Triptolide Nanoparticles.
Wang C; Shan Y; Yang J; Xu X; Zhuang B; Fan Y; Xu W
J Biomed Nanotechnol; 2015 May; 11(5):805-15. PubMed ID: 26349393
[TBL] [Abstract][Full Text] [Related]
9. KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs.
Liu H; Sun M; Liu Z; Kong C; Kong W; Ye J; Gong J; Huang DCS; Qian F
J Control Release; 2019 Feb; 296():40-53. PubMed ID: 30653981
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tissue distribution study in mice of triptolide-loaded lipid emulsion and accumulation effect on pancreas.
Li X; Mao Y; Li K; Shi T; Yao H; Yao J; Wang S
Drug Deliv; 2016 May; 23(4):1344-54. PubMed ID: 25853479
[TBL] [Abstract][Full Text] [Related]
11. Triptolide-targeted delivery methods.
Xu H; Liu B
Eur J Med Chem; 2019 Feb; 164():342-351. PubMed ID: 30605832
[TBL] [Abstract][Full Text] [Related]
12. Triptolide enhances TRAIL sensitivity of pancreatic cancer cells by activating autophagy via downregulation of PUM1.
Dai H; Jiang Y; Luo Y; Bie P; Chen Z
Phytomedicine; 2019 Sep; 62():152953. PubMed ID: 31128486
[TBL] [Abstract][Full Text] [Related]
13. Targeted Delivery and Sustained Antitumor Activity of Triptolide through Glucose Conjugation.
He QL; Minn I; Wang Q; Xu P; Head SA; Datan E; Yu B; Pomper MG; Liu JO
Angew Chem Int Ed Engl; 2016 Sep; 55(39):12035-9. PubMed ID: 27574181
[TBL] [Abstract][Full Text] [Related]
14. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth.
Pan T; Zhang Y; Zhou N; He X; Chen C; Liang L; Duan X; Lin Y; Wu K; Zhang H
Oncotarget; 2016 Jul; 7(28):44299-44309. PubMed ID: 27322423
[TBL] [Abstract][Full Text] [Related]
15. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
16. Synergism of cytotoxicity effects of triptolide and artesunate combination treatment in pancreatic cancer cell lines.
Liu Y; Cui YF
Asian Pac J Cancer Prev; 2013; 14(9):5243-8. PubMed ID: 24175808
[TBL] [Abstract][Full Text] [Related]
17. Primary and liver metastasis-derived cell lines from KrasG12D; Trp53R172H; Pdx-1 Cre animals undergo apoptosis in response to triptolide.
Sangwan V; Banerjee S; Jensen KM; Chen Z; Chugh R; Dudeja V; Vickers SM; Saluja AK
Pancreas; 2015 May; 44(4):583-9. PubMed ID: 25875797
[TBL] [Abstract][Full Text] [Related]
18. Triptolide-loaded nanoparticles targeting breast cancer in vivo with reduced toxicity.
Zheng W; Wang C; Ding R; Huang Y; Li Y; Lu Y
Int J Pharm; 2019 Dec; 572():118721. PubMed ID: 31626922
[TBL] [Abstract][Full Text] [Related]
19. Development of triptolide-nanoemulsion gels for percutaneous administration: physicochemical, transport, pharmacokinetic and pharmacodynamic characteristics.
Yang M; Gu Y; Yang D; Tang X; Liu J
J Nanobiotechnology; 2017 Dec; 15(1):88. PubMed ID: 29202753
[TBL] [Abstract][Full Text] [Related]
20. Autophagy in pancreatic cancer: an emerging mechanism of cell death.
Mujumdar N; Saluja AK
Autophagy; 2010 Oct; 6(7):997-8. PubMed ID: 20818166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
